Tinnitus and old age presbycusis.
Conditions
Interventions
Trade Name: MIRAPEXIN
Product Name: Mirapexin
Pharmaceutical Form: Tablet
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Sponsors
Medical and Health Science Center, University of Debrecen Dept. of Otolaryngology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Age over 50 years, Tinnitus, Presbycusis Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Conductive hearing loss Menier disease Other innear ear deafness Neuro degenerative disease Not controlled hypertension Cardiac decompensation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To study the putative efficacy of Mirapexin on tinnitus and presbycusis.;Secondary Objective: ;Primary end point(s): Hearing after 4 weeks and 12 weeks after one month treatment. | — |
Countries
Hungary
Outcome results
None listed